

PFIZER INC  
Form SC 13D  
September 17, 2003

OMB APPROVAL  
OMB Number:  
3235-0145  
Expires: December 31,  
2005  
Estimated average  
burden  
hours per response . .  
11

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)\*

Onyx Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value \$0.001 per share
(Title of Class of Securities)
683399 10 9
(CUSIP Number)
Margaret M. Foran Vice President - Corporate Governance and Secretary 235 East 42 <sup>nd</sup> Street New York, N.Y. 10017

Edgar Filing: PFIZER INC - Form SC 13D

212-733-4802

(Name, Address, and Telephone Number of Person Authorized to  
Receive Notices and Communications)

July 22, 2003

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sec. 240.13d-1(e), 240.13D(f) or 240.13d-1 (g), check the following box. [ ]

Note

: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Sec. 240.13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of Information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

CUSIP No. 683399 10 9

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

Warner-Lambert Company LLC; 22-1598912

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

Edgar Filing: PFIZER INC - Form SC 13D

(b)

3. SEC Use Only .....
  4. Source of Funds (See Instructions) .....WC.....
  5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
  6. Citizenship or Place of Organization Delaware
- 
- |   |     |                             |
|---|-----|-----------------------------|
|   | 7.  | Sole Voting Power 1,398,079 |
| Number of Shares Beneficially Owned by Each Reporting Person With | 8.  | Shared Voting Power         |
|   |     | Sole Dispositive Power      |
|   | 9.  | 1,398,079                   |
|   | 10. | Shared Dispositive Power    |
- 
11. Aggregate Amount Beneficially Owned by Each Reporting Person  
1,398,079 ..
  12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares  
(See Instructions)
  13. Percent of Class Represented by Amount in Row (11) 4.8%
  14. Type of Reporting Person (See Instructions) CO

This Amendment No. 5 (this "Amendment") to the Statement on Schedule 13D filed by Warner-Lambert Company, a Delaware corporation ("Purchaser"), on May 9, 1996 and amended on July 1, 1997, February 28, 2000 and June 4, 2003 (the "Schedule 13D"), relates to the common stock, par value \$.001 per share (the "Common Stock"), of Onyx Pharmaceuticals, Inc., a Delaware corporation ("Issuer") amends such Statement as follows: (All capitalized terms used but not defined herein have the meaning ascribed to them in the Schedule 13D).

1. Item 5 is amended by adding the following:

Edgar Filing: PFIZER INC - Form SC 13D

(e) Purchaser ceased to be the beneficial owner of more than five percent (5%) of Issuer's Common Stock on July 22, 2003, at which time Issuer sold an additional 5,000,000 shares of Common Stock in an underwritten public offering.

*Signature*

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date 9/16 /2003
/s/ Susan Grant
Name/Title: Susan Grant, Assistant Secretary

OMB APPROVAL  
OMB Number:  
3235-0145  
Expires: December 31,  
2005  
Estimated average  
burden  
hours per response . .  
11

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D  
Under the Securities Exchange Act of 1934  
(Amendment No. 5)\*

Edgar Filing: PFIZER INC - Form SC 13D

Onyx Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value \$0.001 per share
(Title of Class of Securities)
683399 10 9
(CUSIP Number)
Margaret M. Foran Vice President - Corporate Governance and Secretary 235 East 42 <sup>nd</sup> Street New York, N.Y. 10017 212-733-4802
(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communications)
July 22, 2003
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sec. 240.13d-1(e), 240.13D(f) or 240.13d-1 (g), check the following box. [ ]

Note

: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Sec. 240.13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Persons who respond to the collection of Information contained in this form are not

Edgar Filing: PFIZER INC - Form SC 13D

required to respond unless the form displays a currently valid OMB control number.

CUSIP No. 683399 10 9

1. Names of Reporting Persons.

I.R.S. Identification Nos. of above persons (entities only).

Pfizer Inc., 13-5315170

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a)

(b)

3. SEC Use Only .....

4. Source of Funds (See Instructions) .....WC.....

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

6. Citizenship or Place of Organization Delaware

Number of Shares Beneficially Owned by Each Reporting Person With	7.	Sole Voting Power 1,398,079
	8.	Shared Voting Power
	9.	Sole Dispositive Power 1,398,079
	10.	Shared Dispositive Power

11. Aggregate Amount Beneficially Owned by Each Reporting Person  
1,398,079 ..

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

13. Percent of Class Represented by Amount in Row (11) 4.8%

14.

Edgar Filing: PFIZER INC - Form SC 13D

Type of Reporting Person (See Instructions) CO